+

WO1999030702A1 - Preparation a base de levodopa absorbable par voie percutanee - Google Patents

Preparation a base de levodopa absorbable par voie percutanee Download PDF

Info

Publication number
WO1999030702A1
WO1999030702A1 PCT/JP1998/005670 JP9805670W WO9930702A1 WO 1999030702 A1 WO1999030702 A1 WO 1999030702A1 JP 9805670 W JP9805670 W JP 9805670W WO 9930702 A1 WO9930702 A1 WO 9930702A1
Authority
WO
WIPO (PCT)
Prior art keywords
levodopa
acid
sensitive adhesive
preparation
transdermal absorption
Prior art date
Application number
PCT/JP1998/005670
Other languages
English (en)
Japanese (ja)
Inventor
Hiroko Udagawa
Takayuki Oka
Masaru Hamabe
Original Assignee
Sekisui Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sekisui Chemical Co., Ltd. filed Critical Sekisui Chemical Co., Ltd.
Priority to AU16817/99A priority Critical patent/AU1681799A/en
Publication of WO1999030702A1 publication Critical patent/WO1999030702A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Definitions

  • the present invention relates to a transdermal preparation containing levodopa.
  • Lepodopa a dopamine precursor
  • Levodopa a dopamine precursor
  • Levodopa in the treatment of Parkinson's disease, in which dyskinesia occurs due to decreased production of dopamine in the brain, levodopa circulates through the body and enters the brain, where it is converted to dopamine by the action of nerve cells to reduce symptoms. Because of its improvement, levodopa is widely used as an effective therapeutic agent (Pharmaceutical Journal; Vo 1.31, No. 12, 1995 / ⁇ . 2998).
  • levodopa administration has the following problems, which can have a significant effect on daily life.
  • Lepodopa is easily metabolized in various tissues, including the gastrointestinal tract, and has a very low rate of translocation into the brain, requiring large doses.
  • intravenous drip infusion requires complicated treatment for long-term treatment, which causes pain to the patient.
  • the present invention has been made in view of the above problems, and an object of the present invention is to provide a levodopa-containing transdermal absorption preparation which can be used easily and has excellent drug efficacy.
  • the percutaneous absorption preparation according to the present invention contains, as a drug, at least one selected from levodopa and a pharmaceutically acceptable ester thereof in a base, and the site where the above-mentioned drug exhibits a drug effect is other than the site of administration. It is unique.
  • the transdermal absorption preparation according to the present invention preferably contains a metabolic inhibitor of levodopa in the base.
  • the content of the drug in the preparation is preferably from 0.1 to 30% by weight.
  • the above-mentioned percutaneous absorption preparation contains, as an additive, at least one selected from the group consisting of an organic acid, a hygroscopic substance, and a surfactant in a base. .
  • the hygroscopic substance at least one selected from the group consisting of a water-absorbing polymer and a polyhydric alcohol is preferably used.
  • the polyhydric alcohol preferably comprises glycerin, propylene glycol, 1,3-butylene glycol, and polyethylene glycol having a molecular weight of from 200 to 600 as determined by a terminal group assay. At least one selected from the group is used.
  • the base is a polymer, a gay acid, a gold silicate earth metal-based mineral, a hydrocarbon, an oil or fat, a polyhydric alcohol, a higher alcohol, a lower alcohol, a higher fatty acid, a fatty acid ester, and water. It consists of at least one selected from the group consisting of:
  • the transdermal absorption preparation is in at least one form selected from the group consisting of a cream, a gel, a paste, a lotion, and a poultice.
  • a pressure-sensitive adhesive layer containing a drug is provided on one surface of a support.
  • the pressure-sensitive adhesive layer at least one selected from the group consisting of an acryl-based pressure-sensitive adhesive, a rubber-based pressure-sensitive adhesive, a silicon-based pressure-sensitive adhesive and a urethane-based pressure-sensitive adhesive is preferably used.
  • the acrylic pressure-sensitive adhesive preferably contains 40 to 90 mol% of (meth) acrylic acid alkyl ester and 10 to 60 mol% of vinylpyrrolidone and has a water absorption of 1.5% or more.
  • a polymer is used.
  • the drug used in the present invention is at least one selected from levodopa and its pharmaceutically acceptable ester, and if its content is too small, sufficient drug efficacy may not be obtained. 0.1 to 30% by weight in the base is preferable because it may adversely affect the physical properties and make it impossible to endure practical use.
  • metabolic inhibitors can also be used.
  • the above metabolic inhibitors include benzylazide hydrochloride and carbidopa, and the content thereof is preferably 0.1 to 30% by weight in the base.
  • the transdermal absorbability of levodopa and / or its ester is enhanced.
  • an organic acid, a hygroscopic substance or a surfactant may be added as an additive to the base.
  • organic acids enhance the solubility of the drug in the base and the skin
  • hygroscopic substances enhance the release of the drug from the base and transfer to the skin
  • surfactants enhance the keratin of the skin It acts on the layer and reduces its lubricity to drugs and other additives.
  • organic acids examples include lauric acid, palmitic acid, stearic acid, oleic acid, adipic acid, pendecilenic acid, lactic acid, citric acid, butyric acid, maleic acid, fumaric acid, lingoic acid, and gallic acid.
  • lactic acid which has a large absorption promoting effect, is preferred.
  • the content of the organic acid is less than 0.1% by weight in the base, the effect of improving the transdermal absorbability of the drug is low, and if it exceeds 20% by weight, skin irritation may occur.
  • the content is preferably 0.1 to 20% by weight, more preferably 0.5 to 10% by weight in the base.
  • Examples of the hygroscopic substance include a water-absorbing polymer and a polyhydric alcohol, and a water-absorbing polymer and a polyhydric alcohol can be particularly preferably used.
  • water-absorbing polymer examples include polyvinylpyrrolidone, crosslinked polyvinylpyrrolidone, polyacrylic acid, polymethacrylic acid, sodium polyacrylate, gelatin, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethyl.
  • Cell mouth sodium carboxymethylcellulose, carboxyvinyl polymer, polyvinyl alcohol, polyvinyl butyral, polyvinyl ether, starch, polyethylene glycol, polypropylene glycol, polyoxyethylene polyoxypropylene block copolymer, ethylene glycol-propylene glycol block Copolymers, dextran and the like.
  • polyhydric alcohol examples include those other than those falling under the category of the water-absorbing polymer, and include, for example, glycerin, butanediol, hexanetriol, propylene glycol, sorbitol, glucose, 1,3-butylene glycol and diethylene glycol. No.
  • hygroscopic substance it is also possible to use polysaccharides such as sorbitol and dextrin; sodium lactate, 2-pyrrolidone-5-sodium carboxylate, and the like.
  • hygroscopic substances may be used alone or in combination of two or more.
  • the polyhydric alcohol it is more preferable to use at least one selected from the group consisting of glycerin, propylene glycol, 1,3-butylene glycol, and polyethylene glycol having a molecular weight in the range of 200 to 600.
  • glycerin glycerin, propylene glycol, 1,3-butylene glycol, and polyethylene glycol having a molecular weight in the range of 200 to 600.
  • These are liquids at 40 ° C or lower, are highly hygroscopic, have a moisturizing effect on the skin, and are extremely low-irritant when applied to the skin. They increase skin permeability by increasing the hydration properties of the skin and transporting organic acids that effectively dissolve levodopa into the skin.
  • the content of the hygroscopic substance is less than 10% by weight, the effect of reducing skin irritation may not be sufficient, and if it exceeds 40% by weight, in the case of a patch, the inside of the adhesive layer Since the cohesive force is excessively reduced and adhesive residue may be generated at the time of release, the content is preferably 10 to 40% by weight, more preferably 15 to 35% by weight in the base.
  • surfactant examples include peraroyl sarcosine, diethanolamide laurate, polyoxyethylene alkyl ether, polyoxyethylene alkylamine, sorbitan fatty acid ester, and polyglycerin fatty acid ester.
  • the content of the above surfactant is less than 0.01% by weight, the effect of improving the skin absorbability of the drug may be too low. Since skin irritation may occur, the content is preferably from 0.1 to 10% by weight, more preferably from 0.1 to 5% by weight in the base.
  • the base used in the present invention is any as long as it can stably retain levodopa and its pharmaceutically acceptable ester and can absorb levodopa and its pharmaceutically acceptable ester into the body when administered to the skin.
  • bases such as ointments, creams, gels, pastes, lotions, and patches can be used.
  • One or a composition containing it is preferred as a base.
  • polymer examples include polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, polyacrylic acid salt (for example, sodium salt), methoxyethylene-maleic anhydride copolymer, polyvinyl ether, and polyacrylic acid.
  • examples include amide, sodium alginate, gelatin, corn starch, tragacanth, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, dextrin, carboxymethyl starch and the like.
  • geic acid and silicate metal earth minerals examples include colloidal hydrated magnesium silicates such as colloidal silicon dioxide, heavy kaolin and bentonite, and colloidal hydrated magnesium silicate such as bi-gum. Pum ⁇ Aluminum-based minerals.
  • hydrocarbons examples include white iselin, paraffin, liquid paraffin, and hydrogel bongel ointment (for example, trade name Plastibase, manufactured by Taisho Pharmaceutical Co., Ltd.).
  • examples of the fats and oils include beeswax, olive oil, cocoa oil, sesame oil, soybean oil, laccase oil, beef tallow, lard, lanolin, castor oil and the like.
  • polyhydric alcohol examples include glycerin, butanediol, hexanetriol, propylene glycol, polyethylene glycol, polypropylene glycol, polyoxyethylene polyoxypropylene block copolymer, and the like.
  • Examples of the higher alcohol include lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, cetostearyl alcohol, and oleyl alcohol.
  • Examples of the lower alcohol include ethyl alcohol and isopropyl alcohol.
  • fatty acids examples include, for example, acetic acid, acrylic acid, pallic acid, lauric acid, tridecylic acid, myristic acid, palmitic acid, stearic acid, oleic acid, arachidonic acid, linoleic acid, and linolenic acid. Saturated or unsaturated fatty acids are mentioned.
  • fatty acid ester examples include an ester of a fatty acid having 8 to 20 carbon atoms and an aliphatic alcohol having 1 to 32 carbon atoms.
  • fatty acids examples include, for example, hydrauric acid, hydrauric acid, lauric acid, tridecylic acid, myristic acid, palmitic acid, stearic acid, pendecilenic acid, oleic acid, arachidonic acid, linoleic acid, linolenic acid, sebacic acid And the like.
  • fatty acid esters include, for example, isopiryl myristate, octyldodecyl myristate, isopropyl palmitate, cetyl palmitate, white wax and the like.
  • the transdermal preparation of the present invention may contain a solubilizer, Accelerators, stabilizers, fillers, antioxidants, tackifiers and the like may be added.
  • the above-mentioned dissolving agents are used to adjust the properties (viscosity, homogeneity, etc.) of the preparation, and include, for example, hydrocarbons such as liquid paraffin; isopropyl myristate, glyceryl monolaurate, and ethyl ethyl sebacate. Esters of fatty acids with monohydric or polyhydric alcohols; and oils and fats derived from natural products such as lanolin and olive oil.
  • the above-mentioned percutaneous absorption enhancer is used to increase the skin permeability of levodopa and its pharmaceutically acceptable ester by acting on the skin. For example, it enhances the hydration of the skin, or enhances levodopa. Good dissolution and transport into the skin enhances skin permeability.
  • percutaneous absorption enhancers include polysorbate, diethanolamide diphosphate, lauroyl sarcosine, polyoxyethylene alkyl ether, polyoxyethylene alkylamine, sorbitan fatty acid ester, and glycerin fatty acid ester. And the like.
  • the stabilizing agent is used to suppress oxidation, decomposition, etc. of levodopa and its pharmaceutically acceptable ester and other components, and to prevent the preparation from changing over time.
  • oxidation, decomposition, etc. of levodopa and its pharmaceutically acceptable ester and other components for example, butylhydroxytoluene, sorbic acid, etc.
  • Antioxidants; cyclodextrin, ethylenediaminetetraacetic acid, etc .; and the above fillers are used for the purpose of adjusting the viscosity and hardness of the preparation, uniform dispersion and retention of levodopa, and the like.
  • examples include calcium carbonate, titanium oxide, lactose, and crystalline cellulose.
  • the transdermal preparation of the present invention can be produced by a conventional method.
  • the necessary base materials are kneaded, emulsified, suspended or dissolved according to the dosage form, and then the drug is manufactured.
  • the drug is manufactured.
  • a solubilizer e.g., a solubilizer, a percutaneous absorption enhancer, a stabilizing agent, a filler, etc., and mixing with a commonly used kneader.
  • the levodopa-containing transdermal absorption preparation of the present invention can also be used as a transdermal patch with a drug-containing pressure-sensitive adhesive layer provided on one surface of a support.
  • the support is not particularly limited as long as the support has a function of protecting the surface opposite to the application surface, and is usually a plastic film or sheet, a tape, a nonwoven fabric, or the like.
  • a single or laminated material such as a woven fabric, a foam sheet, or a metal foil (for example, an aluminum foil) is used.
  • the support those having flexibility capable of following the movement of the skin surface and barrier properties for preventing the escape of drugs and other additives are preferably used.
  • polyester copolymers such as polyethylene terephthalate and polyvinyl terephthalate; polyethylene, polypropylene, polybutadiene, polybutene, and ethylene-vinyl acetate copolymers.
  • Polyolefin (co) polymers such as polymer, ethylene-propylene copolymer, ethylene-alkyl (meth) acrylate copolymer, ethylene-methyl acrylate copolymer; styrene-isoprene-styrene copolymer Styrene-based copolymers such as styrene-butadiene-styrene copolymers and hydrogenated products thereof; vinylidene chloride-based (co) polymers such as polyvinylidene chloride and vinylidene chloride-styrene copolymer; Vinyl, vinyl chloride-ethylene copolymer, chloride Vinyl chloride-based (co) polymers such as vinyl-acrylic acid alkyl ester copolymers; silicone resins; polyfluoroethylene; polyurethane; and polyimides.
  • polymers such as polymer, ethylene-propylene copolymer, ethylene-alkyl (meth) acrylate copo
  • Examples of the material of the nonwoven fabric and the woven fabric include fibrous materials made of acryl-based resins such as polyester, polyolefin, and atarilonitrile, polyamide, rayon, and cotton.
  • Examples of the material of the foam include polyethylene, polypropylene, ethylene-propylene copolymer, ethylene-vinyl acetate copolymer, polyolefin-based resin such as polyethylene oxide; and styrene-butadiene copolymer. No.
  • the thickness of the support is too thin, the strength of the preparation is insufficient, and the skin tends to become stiff at the time of application.When it is thick, the discomfort when applied to the skin increases, and the thickness of the support becomes poor due to the sticking of the application end. It is preferably 20 to 300, because it may be easily damaged.
  • the thickness of the support varies depending on the material used, but in the case of a film, the thickness is preferably 500 / im or less, more preferably 40 to 200 ⁇ m.
  • the base used in the pressure-sensitive adhesive layer is a base that stably holds levodopa and a pharmaceutically acceptable ester thereof and that can absorb levodopa and its pharmaceutically acceptable ester into the body when administered to the skin.
  • a base that stably holds levodopa and a pharmaceutically acceptable ester thereof and that can absorb levodopa and its pharmaceutically acceptable ester into the body when administered to the skin.
  • those conventionally used as bases for non-hydrous or hydrous plasters, tapes, patches, cataplasms and the like can be used.
  • the above-mentioned base include, for example, polymers such as acryl, rubber, silicone, and urethane, as required, a crosslinking agent, a plasticizer, a stabilizer, water, a pH adjuster, and a filler. And the like.
  • a pressure-sensitive adhesive mainly composed of an alkyl (meth) acrylate is preferred, and a functional monomer and Z or a polyfunctional monomer copolymerizable with the alkyl (meth) acrylate are preferred. And a copolymer thereof.
  • alkyl (meth) acrylate examples include: (meth) methyl acrylate, (meth) ethyl acrylate, (meth) propyl acrylate, (meth) isopropyl acrylate, and (meth) acrylic acid n-butyl.
  • Examples of the functional monomer include a monomer having a hydroxyl group, a monomer having a hydroxyl group, a monomer having an amide group, a monomer having an amino group, a monomer having a nitrogen-containing heterocyclic ring, and the like. Specific examples include (meth) acrylic acid-2-hydroxyhydroxyl, (meth) acrylic acid-12-hydroxypropyl, (meth) acrylic acid, maleic acid, acrylamide, ethoxymethylacrylic acid. Media, diacetone acrylamide, dimethylaminoethyl acrylate, vinyl pyrrolidone, vinyl imidazole and the like.
  • polyfunctional monomers examples include, for example, alkylene glycol which is a reaction product of (meth) acrylic acid and alkylene glycols; ethylene glycol, butylene glycol, hexamethylene glycol, and the like. Di (meth) acrylate, (meth) acrylic acid and polyalkylene glycols; polyalkylene glycol di (meth) acrylate, which is a reaction product of polyethylene glycol, polypropylene dalicol, and the like.
  • the rubber-based adhesive examples include natural rubber, styrene-butadiene rubber, polyisobutylene, styrene-isoprene-styrene block copolymer, styrene-butadiene-styrene block copolymer, and styrene-olefin-styrene block copolymer.
  • Polymers. These are generally used by adding a tackifier such as rosin, hydrogenated rosin, rosin ester, terpene resin, terpene phenol resin, petroleum resin, cumarone resin, and cumarone-indene resin.
  • silicon-based pressure-sensitive adhesive examples include polydimethylsiloxane and polydimethylsiloxane.
  • any urethane-based pressure-sensitive adhesive that has been conventionally used as a pressure-sensitive adhesive for transdermal patches can be used, and is not particularly limited.
  • crosslinking agent examples include aluminum hydroxide, calcium hydroxide, magnesium stearate, isocyanates, epoxy resins, melamine resins, urea resins, and ammoniums.
  • plasticizer those similar to those used as the solubilizer can be used.
  • hydrocarbons such as liquid paraffin; isopropyl myristate, glyceryl monolaurate, and getyl sebacate Esters of fatty acids with monohydric or polyhydric alcohols; higher fatty acids such as oleic acid and lauric acid; higher alcohols such as octyldodecanol and myristyl alcohol; natural such as lanolin, olive oil, and coconut oil Fats and oils derived from products.
  • the content of the above plasticizer is appropriately determined depending on the amount of levodopa and its pharmaceutically acceptable ester and the type of the above-mentioned pressure-sensitive adhesive, but when the content is small, the plasticizing effect is reduced, and when the content is large, the sticking property is reduced. Therefore, the content is preferably 1 to 50% by weight in the pressure-sensitive adhesive layer.
  • the same stabilizers and fillers as those described above can be used.
  • a pressure-sensitive adhesive mainly containing a copolymer composed of 40 to 90 mol% of (meth) acrylic acid alkyl ester and 10 to 60 mol% of vinylpyrrolidone can be suitably used.
  • the copolymer comprising the alkyl (meth) acrylate 40 to 90 mol% and vinylpyrrolidone 10 to 60 mol% may be selected from the alkyl (meth) acrylates according to the required adhesive properties.
  • a monomer copolymerizable with the ester may be added.
  • Examples of the monomer copolymerizable with the alkyl (meth) acrylate include, for example, vinyl acetate, diacetone acrylamide, atarilonitrile, dimethyl acrylamide, and ethylene glycol mono (meth) acrylic acid. Examples include esters and styrene.
  • the constituent components of the copolymer consisting of the above-mentioned alkyl (meth) acrylate 40 to 90 mol% and vinylpyrrolidone 10 to 60 mol% a monomer copolymerizable with the above-mentioned alkyl (meth) acrylate can be used.
  • the proportion of the monomer is preferably not more than 40 mol%, which does not adversely affect the adhesiveness and cohesiveness of the adhesive.
  • the component of the copolymer consisting of 10 to 60 mol% of rupyrrolidone may contain a polyfunctional monomer having two or more polymerizable double bonds in one molecule.
  • the polyfunctional monomer include divinylbenzene, methylene bisacrylamide, ethylene glycol di (meth) acrylate, propylene glycol (meth) acrylate, and polyethylene glycol
  • Examples thereof include (meth) acrylate, hexylene glycol di (meth) acrylate, polyethylene glycol di (meth) acrylate, polypropylene glycol di (meth) acrylate, and trimethylolpropanetri (meth) acrylate.
  • the copolymer is partially crosslinked, that is, in a so-called slightly crosslinked state, and a copolymer having a higher degree of polymerization can be obtained.
  • the fine cross-linking imparts appropriate cohesiveness to the pressure-sensitive adhesive, increases the adhesiveness, prevents adhesive residue upon separation, and improves the stability of the pressure-sensitive adhesive solution.
  • the amount of the polyfunctional monomer used is too small, the aggregation effect cannot be obtained, and if the amount is too large, the reaction solution is likely to gel or is unstable, so the above (meth) acrylic acid alkyl ester 40 to 9
  • 0.001 to 0.1 mol% is preferred, more preferably 0.003 to 0.1 mol%. 07 mol%.
  • the copolymer consisting of 40 to 90 mol% of the alkyl (meth) acrylate and 10 to 60 mol% of vinylpyrrolidone has a water absorption rate so that a large amount of a hygroscopic substance can be retained. Should be 1.5% or more.
  • the water absorption is the ratio of the increased weight to the initial weight after storage for 10 days in an atmosphere adjusted to 25 ° C; 90% relative humidity.
  • the water absorption of the copolymer consisting of the alkyl (meth) acrylate 40 to 90 mol% and vinylpyrrolidone 10 to 60 mol% is caused by vinylpyrrolidone in the copolysynthesis, especially vinylpyrrolidone. Is significantly increased by the presence of a block in the copolymer. Therefore, in order to increase the water absorption, it is preferable to use a vinylpyrrolidone block copolymer or a graft copolymer.
  • Examples of the method for producing the block copolymer or the graft copolymer include a macromonomer, a reactive monomer, and living polymerization.
  • the copolymer consisting of the alkyl (meth) acrylate 40 to 90 mol% and vinylpyrrolidone 10 to 60 mol% does not require the vinylpiperidone to be completely present in a block form. It is sufficient that vinyl viridone is present in the copolymer in a rich composition.
  • the above copolymer of alkyl (meth) acrylate of 40 to 90 mol% and vinyl pyrrolidone of 10 to 60 mol% having a water absorption of 1.5% or more is, for example, vinylpyrrolidone at the start of polymerization. 90% or more of the total amount of the dong and 0.1 to 5% of the total amount of the alkyl (meth) acrylate coexist, and at least the initial stage of the polymerization (the polymerization rate is 10% or less).
  • the alkyl (meth) acrylates are successively added. Can be obtained by a solution polymerization method in which the remainder is added.
  • solvent used for the solution polymerization examples include ester solvents such as ethyl acetate, propyl acetate, and butyl peroxide; ketone solvents such as methyl ethyl ketone and cyclohexanone; and aromatic solvents such as benzene and toluene. ; Cellosolve-based solvents such as Solvent in Tiltose and Solvent in Etilse are listed. These may be used alone or in combination of two or more.
  • a generally used thermal radical polymerization initiator can be used, and specific examples thereof include hydroxycarbonate, ketone peroxide, and peroxide.
  • Organic peroxides such as ketals, hydropoxides, dialkylpoxides (eg, lauroylpoxides, benzoylpoxides, etc.), diasilboxides, and peroxyesters; 2,2'-azobisisobutyrate Lonitrile, 2, 2'-azobis (2-methylbutyronitrile), 2,2, -azobis (2,4-dimethylvaleronitrile), 2,
  • Azo compounds such as dimethyl 2'-azobisisobutyrate. These may be used alone or in combination of two or more.
  • the amount of the polymerization initiator to be used is preferably 0.001 to 5 parts by weight based on 100 parts by weight of the monomers constituting the copolymer.
  • a predetermined amount may be initially supplied collectively, or may be supplied separately.
  • the method for producing the transdermal patch of the present invention varies depending on the kind of the adhesive, but the adhesive layer can be produced by a conventional method such as a hot melt method, a solution method, and a solvent coating method.
  • a drug and, if necessary, other components are added to the pressure-sensitive adhesive solution obtained by polymerization, followed by stirring and mixing. This solution is After applying on a release paper and drying, the support is heat-laminated to prepare a transdermal patch.
  • the pressure-sensitive adhesive composition may be once coated on a release paper and dried to form a pressure-sensitive adhesive layer, and then the pressure-sensitive adhesive layer may be transferred to a support and laminated.
  • the thickness of the pressure-sensitive adhesive layer is not particularly limited. However, if the thickness of the pressure-sensitive adhesive layer is less than 20 m, it becomes difficult to contain a necessary amount of the drug. Usually, 20 to 100 / m is preferable because the efficiency is reduced.
  • a pretreatment such as an undercoating treatment, a corona discharge treatment, a chemical oxidation treatment, and an ozone treatment may be performed in order to enhance the adhesiveness.
  • the release paper is used for the purpose of protecting the pressure-sensitive adhesive layer, and is usually formed by releasing the surface of a single layer or a laminate of a plastic film, paper, or the like with silicone or the like. used.
  • the thickness of the release paper is usually preferably 300 ⁇ m or less, more preferably 10 ⁇ 200 ⁇ .
  • plastic film of the release paper examples include polyethylene terephthalate, polyethylene, polypropylene, polyvinyl chloride, and polyvinylidene chloride.
  • Examples of the paper include a paper impregnated with polyvinyl alcohol or the like.
  • Levodopa (1.23 g) was suspended in glycerin (1.987 g), and 3.51 g of clospovidone (a crosslinked polymer of 1-vinyl-2-pyrrolidone) was added to the suspension.
  • clospovidone a crosslinked polymer of 1-vinyl-2-pyrrolidone
  • levodopa (1.44 g) suspended in glycerin (2.49) and clospovidone (1-vinyl) in 6.2.75 g of a solution of the polymer in ethyl acetate (solid content: 3.5.76%) — Crosslinked polymer of 2-pyrrolidone) 2.
  • 49 g was added and uniformly mixed to obtain a coating liquid.
  • the obtained coating liquid was applied onto a siliconized polyethylene terephthalate (PET) film having a thickness of 35 tzm so that the levodopa content was 0.75 mgZcm 2, and the coating was performed at 60 with 30. After drying for a minute, an adhesive layer was obtained.
  • a transdermal patch was prepared by laminating the EVA side of a support composed of a laminate of PET film and ethylene-vinyl monoxide copolymer (EVA) on the obtained pressure-sensitive adhesive layer.
  • EVA ethylene-vinyl monoxide copolymer
  • CMC-Na sodium carboxycellulose
  • Example 1 The whole back of New Zealand White (male, 1 year old) was shaved and the transdermal preparation obtained in Examples 1 and 2 was applied as a repo-dopa to an area of 200 cm2 above the skin as a reportopa.
  • Each animal was applied to two egrets (Example 1: 3 g applied, Example 2: applied in a size of 200 cm 2 ).
  • the preparation obtained in Comparative Example 1 was orally administered to other egrets at a concentration of 1 lmg / kg of levodopa (about 5 OmgZ individuals as levodopa). After each administration, blood was collected over time up to 24 hours, and the concentration of levodopa in the plasma was measured by high performance liquid mouth chromatography. The results are shown in Table 1.
  • ND means not detected.
  • Ethyl acetate was added to 1.0 g of lauroyl peroxyside to prepare a solution having a total volume of 30 ml. This solution was copolymerized while being dropped at a rate of 1 m 1 Zh to the monomer composition solution.
  • the copolymerization was stopped, and ethyl acetate was added so that the solid content was 30% by weight.
  • the mixture was mixed to obtain a solution of the adhesive A in ethyl acetate.
  • the water absorption of the adhesive A was measured and found to be 12.4%.
  • composition shown in Table 2 a drug, an adhesive solution, a hygroscopic substance, an organic acid, a surfactant, an additive, and a metabolic inhibitor were mixed so as to be uniform throughout to obtain a coating liquid.
  • This coating solution was spread on a polyethylene terephthalate film so as to have a thickness after drying of 150 / zm, dried at 60 ° C for 30 minutes, and adhered. An agent layer was formed. A laminating film of polyester 12 // m ethylene-vinyl acetate copolymer resin 2 O ⁇ m was adhered to the pressure-sensitive adhesive layer to obtain a patch. Table 2
  • Hygroscopic substance * 1 Gly: glycerin, PG: propylene glycol surfactant BL9: polyoxyethylene (9) lauryl ether,
  • Lepodopa blood concentration was measured over time using a rat, and the area under the blood concentration curve (AUC) at 24 hours was calculated.
  • the AUC of each of the examples was at least 300 ng ⁇ hr / L, and the AUC of the comparative example was at most 600 ng ⁇ hr / L. It can be seen that the percutaneous absorbability is significantly improved. Also, AUC at oral administration is 2 6 5 0 ng * h rZL , in the embodiment, c (stability test were all found to be continuously absorbed levodopa one day )
  • the efficacy of the transdermal preparation containing levodopa was evaluated using the rat (the inhibitory effect on haloperidol-induced talepsi).
  • the back of a wister rat male, 7 weeks old was shaved, and the samples of Examples and Comparative Examples were respectively applied to the skin in an area of 12 cm 2 .
  • the haloperidol solution was orally administered so that the dose of fodoperidol was 1.0 mg Z kg.
  • the efficacy of levodopa was evaluated by the following measurement method. For the evaluation of drug efficacy, rats were used in groups of 10 rats, and the number of rats that showed a suppuration effect was evaluated.
  • the evaluation method was to install a stainless steel pipe with a diameter of 2 mm horizontally at a height of 7 cm.
  • the mouse is forcibly hooked with both forelimbs on this pipe, and the posture holding until both forelimbs are separated from the pipe is determined to be force talepsi.
  • the percutaneous absorption preparation of the present invention is a levodopa-containing percutaneous absorption preparation containing, as a drug, at least one selected from levodopa and a pharmaceutically acceptable ester thereof in a base, so that administration is simple. Yes, excellent persistence of effective blood concentration. For this reason, it is possible to prepare a preparation with less side effects and less fluctuation in drug efficacy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une préparation à base de lévodopa pouvant être absorbée par voie percutanée, laquelle est utilisée facilement et présente une excellente persistance de l'efficacité du médicament. La préparation contient au moins un élément choisi entre la lévodopa et ses esters acceptables sur le plan pharmaceutique constituant le médicament dans la base, le médicament exerçant ses effets sur un site autre que le site d'administration.
PCT/JP1998/005670 1997-12-17 1998-12-16 Preparation a base de levodopa absorbable par voie percutanee WO1999030702A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16817/99A AU1681799A (en) 1997-12-17 1998-12-16 Percutaneously absorbable levodopa-containing preparation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP34799497 1997-12-17
JP9/347994 1997-12-17
JP23418298 1998-08-20
JP10/234182 1998-08-20

Publications (1)

Publication Number Publication Date
WO1999030702A1 true WO1999030702A1 (fr) 1999-06-24

Family

ID=26531412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/005670 WO1999030702A1 (fr) 1997-12-17 1998-12-16 Preparation a base de levodopa absorbable par voie percutanee

Country Status (2)

Country Link
AU (1) AU1681799A (fr)
WO (1) WO1999030702A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
JPWO2019171843A1 (ja) * 2018-03-05 2021-02-25 パナソニックＩｐマネジメント株式会社 化粧料または医療材料

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
WO1998016208A1 (fr) * 1996-10-13 1998-04-23 Analyst Research Lab Methodes et appareil de traitement de la maladie de parkinson

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
WO1998016208A1 (fr) * 1996-10-13 1998-04-23 Analyst Research Lab Methodes et appareil de traitement de la maladie de parkinson

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MUTSUO OKUMURA, KENJI SUGIBAYASHI, YASUNORI MORIMOTO: "EFFECT OF SEVERAL ENHANCERS ON THE SKIN PERMEATION OF WATER-SOLUBLEDRUGS", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 37, no. 05, 1 May 1989 (1989-05-01), JP, pages 1375 - 1378, XP002922309, ISSN: 0009-2363 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
JPWO2019171843A1 (ja) * 2018-03-05 2021-02-25 パナソニックＩｐマネジメント株式会社 化粧料または医療材料

Also Published As

Publication number Publication date
AU1681799A (en) 1999-07-05

Similar Documents

Publication Publication Date Title
JP2849950B2 (ja) 経皮吸収製剤
US20050187212A1 (en) Pharmaceutical composition for topical delivery of meloxicam
CZ20013763A3 (cs) Transdermální terapeutický systém s neutralizovaným akrylátovým adhezivním lepidlem
US4954343A (en) Dermal pharmaceutical preparations
WO2002032431A1 (fr) Compositions pour preparations externes
KR20090049597A (ko) 첩부제
JP2820306B2 (ja) 経皮吸収製剤
WO2012090322A1 (fr) Timbre
JP2009203213A (ja) 経皮吸収医薬組成物
JP2011074035A (ja) 貼付剤
JP4851671B2 (ja) トラニラスト経皮吸収貼付剤およびその製造方法
JP3554573B2 (ja) アスピリン含有経皮吸収製剤
KR20090051191A (ko) 첩부제
JPH11209271A (ja) 経皮吸収製剤
WO1999030702A1 (fr) Preparation a base de levodopa absorbable par voie percutanee
WO2004071499A1 (fr) Emplatre contenant du diclofenac
JPH0339488B2 (fr)
JPS6066759A (ja) 医薬製剤
JPWO2009113504A1 (ja) 貼付剤
JPH0753671B2 (ja) 経皮・経粘膜製剤
JP3676567B2 (ja) 医療用粘着剤組成物及び医療用貼付剤
JP5510906B2 (ja) 貼付剤
JPH11209270A (ja) 経皮吸収製剤
JPH085806B2 (ja) 経皮吸収製剤
JP2647222B2 (ja) 経皮吸収製剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载